Physician profile
Michael E Batipps
NPI 1013941137
$5,598.06
in general payments reported to CMS, 2019-2025
31 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,245 · 2020: $797 · 2021: $935 · 2022: $941 · 2023: $788 · 2024: $711 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,679.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $793.00 | 2021-2025 | Ubrelvy, Qulipta |
| Biogen, INC. | $729.56 | 2019-2025 | Tysabri, Vumerity |
| Novartis Pharmaceuticals Corporation | $664.91 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $557.25 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $355.39 | 2019-2021 | |
| Genzyme Corporation | $325.21 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $271.56 | 2023-2024 | Aptiom |
| Celgene Corporation | $250.95 | 2021-2023 | Zeposia |
| Ucb, INC. | $199.66 | 2019-2023 | Nayzilam |
| Tg Therapeutics, INC. | $169.88 | 2024 | |
| Lundbeck LLC | $145.19 | 2022-2025 | Vyepti |
| Emd Serono, INC. | $137.28 | 2019 | |
| Lilly USA, LLC | $134.41 | 2019-2021 | |
| Amgen INC. | $129.06 | 2021-2025 | Uplizna |
| Catalyst Pharmaceuticals, INC. | $96.02 | 2023-2024 | Fycompa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $93.87 | 2022-2024 | |
| Genentech USA, INC. | $71.80 | 2019-2024 | Ocrevus |
| Alnylam Pharmaceuticals INC. | $61.25 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $57.12 | 2020-2021 | |
| Almatica Pharma LLC | $56.65 | 2021 | |
| Axsome Therapeutics, INC. | $49.52 | 2025 | Symbravo |
| Acorda Therapeutics, INC | $40.33 | 2019 | |
| Alexion Pharmaceuticals, INC. | $40.00 | 2019-2020 | |
| Pfizer INC. | $38.34 | 2023 | |
| Vertical Pharmaceuticals, LLC | $29.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.63 | 2021 | |
| Mallinckrodt Enterprises LLC | $19.27 | 2019 | |
| Neurocrine Biosciences, INC. | $17.63 | 2024 | Ingrezza |
| Bausch Health US, LLC | $15.38 | 2021 | |
| Assertio Therapeutics, INC. | $14.70 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Batipps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.